NCT06088264

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986322 in Healthy Adult Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.

Conditions

• Healthy Male Participants

Interventions

Type	Name	Description
DRUG	BMS-986322	Specified dose on specified days.

Timeline

• Start date: 2023-10-31
• Primary completion: 2023-12-22
• Completion: 2023-12-22
• First posted: 2023-10-18
• Last updated: 2024-03-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study